Cost-effectiveness of liver transplantation versus last-resort systemic therapy for colorectal liver metastases. Issue 6 (12th March 2022)

• Record Type: Journal Article
• Authors: Bjørnelv, Gudrun M W; Zolic-Karlsson, Zinajda; Dueland, Svein; Line, Pål-Dag; Aas, Eline
• Is Part Of: British journal of surgery. Volume 109:Issue 6(2022)
• Page Start: 483
• Page End: 485
• Publication Date: 2022-03-12
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znac022
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract : This study estimated the cost-effectiveness of liver transplantation in patients with colorectal liver metastases confined to the liver with progressive disease, compared with alternative treatment options: TAS-102, regorafenib, or best supportive care. Using a mathematical simulation model, people's life expectancy and healthcare costs over 25 years were estimated. Transplanted patients lived for 4.28 years, more than 3 years longer than those who received alternative treatment options. Despite this, the high cost of liver transplantation meant that this treatment was cost-effective only at high willingness-to-pay thresholds.